This section of the FEDERAL REGISTER contains documents other than rules or proposed rules that are applicable to the public. Notices of hearings and investigations, committee meetings, agency decisions and rulings, delegations of authority, filing of petitions and applications and agency statements of organization and functions are examples of documents appearing in this section.

DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board
[B–04–2021]

Foreign-Trade Zone (FTZ) 22—Chicago, Illinois, Notification of Proposed Production Activity, AbbVie, Inc. (Pharmaceutical Products), North Chicago and Lake County, Illinois

AbbVie, Inc. (AbbVie) submitted a notification of proposed production activity to the FTZ Board for its facilities in North Chicago and Lake County, Illinois. The notification conforming to the requirements of the regulations of the FTZ Board (15 CFR 400.22) was received on January 27, 2021.

AbbVie already has authority to produce pharmaceutical products within Subzone 22S. The current request would add a finished product and a foreign status material to the scope of authority. Pursuant to 15 CFR 400.14(b), additional FTZ authority would be limited to the specific foreign-status material and specific finished product described in the submitted notification (as described below) and subsequently authorized by the FTZ Board.

Production under FTZ procedures could exempt AbbVie from customs duty payments on the foreign-status materials/components used in export production. On its domestic sales, for the foreign-status materials/components noted below and in the existing scope of authority, AbbVie would be able to choose the duty rates during customs entry procedures that applies to IMBRUVICA® tablets (duty-free). AbbVie would be able to avoid duty on foreign-status components which become scrap/waste. Customs duties also could possibly be deferred or reduced on foreign-status production equipment.

The material sourced from abroad is ibritunib active pharmaceutical ingredient (duty rate 6.5%). The request indicates that ibritunib is subject to duties under Section 301 of the Trade Act of 1974 (Section 301), depending on the country of origin. The applicable Section 301 decisions require subject merchandise to be admitted to FTZs in privileged foreign status (19 CFR 146.41).

Public comment is invited from interested parties. Submissions shall be addressed to the Board’s Executive Secretary and sent to: ftz@trade.gov. The closing period for their receipt is March 15, 2021.

A copy of the notification will be available for public inspection in the “Reading Room” section of the Board’s website, which is accessible via www.trade.gov/ftz.

For further information, contact Christopher Wedderburn at Chris.Wedderburn@trade.gov.


Andrew McGilvray,
Executive Secretary.

[FR Doc. 2021–02334 Filed 2–2–21; 8:45 am]  
BILLING CODE 3510–OS–P

DEPARTMENT OF COMMERCE

International Trade Administration
[A–549–833]

Citric Acid and Certain Citrate Salts From Thailand: Partial Rescission of Antidumping Duty Administrative Review, 2019–2020

AGENCY: Enforcement and Compliance, International Trade Administration, Department of Commerce.

SUMMARY: The Department of Commerce (Commerce) is rescinding the administrative review of the antidumping duty order on citric acid and certain citrate salts (citric acid) from Thailand covering the period of review (POR) July 1, 2019, through June 30, 2020, in part, with respect to Niran (Thailand) Co., Ltd. (Niran), based on a timely withdrawal of the request for review for Niran.


SUPPLEMENTARY INFORMATION:

Background

On July 1, 2020, Commerce published in the Federal Register a notice of opportunity to request an administrative review of the antidumping duty order on citric acid from Thailand for the period July 1, 2019, through June 30, 2020.1 Based on timely requests from COFCO Biochemical (Thailand) Co., Ltd. (COFCO), Sunshine Biotech International Co., Ltd. (Sunshine), and Archer Daniels Midland Company, Cargill, Incorporated, and Tate & Lyle Ingredients Americas LLC, domestic producers of the subject merchandise and petitioners in the original investigation (collectively, the petitioners),2 on September 3, 2020, in accordance with 751(a)(1) of the Tariff Act of 1930, as amended (the Act), Commerce published in the Federal Register a notice of initiation of administrative review covering COFCO, Sunshine, and Niran.3 On September 17, 2020, Commerce selected COFCO and Sunshine for individual examination and issued the antidumping duty questionnaire to the companies.4

On September 18, 2020, Niran filed a no-shipment certification.5 On October 8, 2020, U.S. Customs and Border Protection (CBP) confirmed that there were no shipments of subject merchandise from Niran during the

---

1 See Antidumping or Countervailing Duty Order, Finding, or Suspended Investigation; Opportunity to Request Administrative Review, 85 FR 30631 (July 1, 2020).